Straits Times Index
3,326.92 -3.17 (-0.10%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,839.92 -248.65 (-0.37%) CMC Crypto 200
1,460.94 -23.75 (-1.60%)
Sandoz Group AG (SDZ.SW)
| Previous close | 32.29 |
| Open | 32.25 |
| Bid | 32.25 x N/A |
| Ask | 32.30 x N/A |
| Day's range | 32.01 - 32.38 |
| 52-week range | 22.70 - 32.80 |
| Volume | |
| Avg. volume | 1,461,165 |
| Market cap | 13.874B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 201.69 |
| EPS (TTM) | 0.16 |
| Earnings date | N/A |
| Forward dividend & yield | 0.45 (1.38%) |
| Ex-dividend date | 03 May 2024 |
| 1y target est | 36.82 |
GlobeNewswireSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
- GlobeNewswire
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f
- GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board membersDividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its
